PASylated factor VIII - XL-protein GmbH

Drug Profile

PASylated factor VIII - XL-protein GmbH

Alternative Names: GNR-021; PAS-clotting factor; xl-180

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XL-protein GmbH
  • Developer International Biotechnology Center Generium; XL-protein GmbH
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 09 Aug 2016 Early research is ongoing in Germany
  • 09 Aug 2016 Preclinical trials in Haemophilia A in Russia and Commonwealth of Independent States (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top